Logo
x

Search

Subscribe Now

Myeloma

Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma

Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma

  • April 19, 2021
Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

  • December 23, 2020
GSK's Belantamab Mafodotin Receives the US FDA Advisory Committee's Recommendation to Treat Relapsed/Refractory Multiple Myeloma

GSK's Belantamab Mafodotin Receives the US FDA Advisory Committee's Recommendation to Treat Relapsed/Refractory Multiple Myeloma

  • July 15, 2020
GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

  • February 4, 2020
Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma

Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma

  • February 12, 2019
J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology

J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up N...

  • August 6, 2018
GSK Reports the US FDA’s BLA Acceptance of Blenrep (Belantamab Mafodotin) Regimen for Treating R/R Multiple Myeloma

    GSK Reports the US FDA’s BLA Acceptance of Blenrep (Belantamab Mafodotin) Regimen for Treating R/R Multiple Myeloma

    • November 25, 2024
    GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

      GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

      • November 14, 2024
      Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma

        Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma

        • November 6, 2024
        Poseida Therapeutics Nominates a New CAR-T Development Candidate Under Partnership with Roche

          Poseida Therapeutics Nominates a New CAR-T Development Candidate Under Partnership with Roche

          • October 18, 2024
          Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

            Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

            • October 16, 2024
            Aurigene Oncology Reports Results from the P-I (SWASTH) Trial of Ribrecabtagene Autoleucel for Multiple Myeloma in India

              Aurigene Oncology Reports Results from the P-I (SWASTH) Trial of Ribrecabtagene Autoleucel for Multiple Myeloma in India

              • October 9, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.